Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prevalence of Significant Liver Fibrosis and Inflammation in Chronic HBV Infected Patients in Grey Zone

NCT05483049 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT05483049
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05483049 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prevalence of Significant Liver Fibrosis and Inflammation in Chronic HBV Infected Patients in Grey Zone
Lead sponsor
Ruijin Hospital
Phase
Observational
Overall status
Unknown status
Start date
September 1, 2022
Completion date
August 31, 2023
Enrollment
600 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b